DFDA

Treprostinil (Parenteral/Inhaled)

Treatment for Pulmonary Arterial Hypertension

Typical Dosage: Highly variable, titrated individually (e.g., IV/SC 1.25 ng/kg/min; inhaled 3-9 breaths 4 times daily)

Effectiveness
90%
Safety Score
30%
Clinical Trials
1
Participants
8K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
30
DangerousModerateSafe
Treatment Details
Dosage Range
Highly variable, titrated individually (e.g., IV/SC 1.25 ng/kg/min; inhaled 3-9 breaths 4 times daily)
Time to Effect
1-2 months (titration)
Treatment Duration
Lifetime
Evidence Quality
HIGH
Number Needed to Treat (NNT)
3(Treat 3 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
5(Treat 5 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$180,000
Monitoring:$10,000
Side Effect Mgmt:$12,000
Total Annual:$202,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POOR
ICER
$400,000/QALY
QALYs Gained
1
Outcome-Based Costs
Cost per Responder
$404,000
Cost per Remission
$2,885,714
Treprostinil (Parenteral/Inhaled) Outcomes

for Pulmonary Arterial Hypertension

Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+50%
Remission Rate
+7%
Common Side Effects
Headache
+70%
Jaw Pain
+50%
Flushing
+40%
Nausea/Diarrhea
+30%
Injection site pain/infection (parenteral)
+85%
Cough (inhaled)
+35%

Sources:

jacc.org
nih.gov
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov

Completed Clinical Trials
1 completed trial for Treprostinil (Parenteral/Inhaled) in Pulmonary Arterial Hypertension

Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication

NCT01268553COMPLETEDPHASE4
View Study
6 participants
INTERVENTIONAL
Tucson, United States +2 more
Started: Aug 1, 2010